Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...

The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.

A breakthrough treatment is making a huge difference for stroke survivors, improving hand and arm function, and their quality ...

Uncover how Ultherapy uses ultrasound to naturally lift and tighten skin, offering a powerful nonsurgical facelift ...

Vir Biotechnology's phase 3 hepatitis programs and cancer trials are on the horizon. Read why VIR stock could benefit from ...

I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform, which can be used to develop cancer treatments by either ...

Researchers are shining a light on cancer cells' energy centers -- literally -- to damage these power sources and trigger widespread cancer cell death. In a new study, scientists combined strategies ...